What question did this study set out to answer?

To evaluate the cost effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) in older adults in Portugal.

March 5, 2026Open Access

Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal

Key Points

To evaluate the cost effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) in older adults in Portugal.
Economic evaluation of vaccine costs and health outcomes
Assessment of cost-effectiveness per age group
Comparison of RZV with standard prevention strategies
RZV is cost-effective for preventing HZ in adults aged 65 years and older.
Cost effectiveness increases for individuals aged 65-69 years due to reduced complication rates.

Abstract

RZV presents a cost-effective option for the prevention of HZ and its complications in Portuguese adults aged ≥ 65 years, with greater cost effectiveness in those aged 65-69 years.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Eleftherios Zarkadoulas

GlaxoSmithKline (Belgium)

Fabio Luiz Carneiro Mourilhe Silva

Joana Alves

Journals

PharmacoEconomics - Open

Actions

Institutions

University of Groningen

University Medical Center Groningen

Universidade Nova de Lisboa

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Cost Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Older Adults in Portugal

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study